FY2025 · ended Dec 31, 2025 · Revenue $159.83M, +1.3% YoY · Filed Mar 12, 2026
Marimed Inc. (MRMD) files with the SEC under industry code 2833, Medicinal Chemicals & Botanical Products. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $159.8 million and a net loss of $14.5 million. Free cash flow was $6.5 million. As of Jun 30, 2026 it held $8.4 million in cash and investments and $94.5 million in total debt.
Revenue (TTM)
$163.82M
+4.5% vs year-ago TTM
Net income (TTM)
$-14.95M
+9.0% vs year-ago TTM
Operating cash flow (TTM)
$9.27M
+368.3% vs year-ago TTM
Free cash flow (TTM)
$8.01M
+461.0% vs year-ago TTM
EPS (TTM)
$-0.04
+11.9% vs year-ago TTM
Dividend per share
None
Shares outstanding
397.88M
+4.1% vs prior year
Net cash
$-86.10M
as of Jun 30, 2026
Operating margin
-1.5%
FY 2026
Company profile
- Industry
- Medicinal Chemicals & Botanical Products (SIC 2833)
- Listed as
- MRMD (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Norwood, MA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1522767
- Former names
- WORLDS ONLINE INC. (until May 15, 2017)
Other Medicinal Chemicals & Botanical Products companies
- Definium Therapeutics, Inc. DFTX
- Regencell Bioscience Holdings Ltd RGC
- Curaleaf Holdings, Inc. CURLF
- Trulieve Cannabis Corp. TRLV
- Cronos Group Inc. CRON
- TFA Therapeutics, Inc. RAJAF
- Tilray Brands, Inc. TLRY
- SNDL Inc. SNDL
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $159.8M | $157.7M | $148.6M | $134.0M | $121.5M |
| Operating income | -$2.8M | $2.6M | $14.4M | $20.4M | $26.9M |
| Net income | -$14.5M | -$12.5M | -$16.0M | $13.5M | $7.2M |
| Diluted EPS | -$0.04 | -$0.03 | -$0.04 | $0.04 | $0.02 |
| Operating cash flow | $7.7M | $6.8M | $7.9M | $7.3M | $35.9M |
| Free cash flow | $6.5M | -$5.2M | -$12.2M | -$4.8M | $18.0M |
| Total assets | $202.6M | $207.0M | $196.1M | $152.2M | $123.2M |
| Total liabilities | $137.8M | $129.4M | $107.2M | $57.2M | $49.2M |
| Stockholders' equity | $50.0M | $58.5M | $68.9M | $57.3M | $36.3M |
| Cash and investments | $8.9M | $7.3M | $15.0M | $9.9M | $29.9M |
| Total debt | $88.7M | $91.7M | $13.8M | $6.1M | $5.7M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Shareholder vote results, Other events
|
Oct 29, 2026 | Oct 28, 2026 |
| 8-K |
Current report
Other events
|
Sep 23, 2026 | Sep 23, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 12, 2026 | Aug 12, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 8, 2026 | Jun 4, 2026 |
| 10-Q | Quarterly report | May 14, 2026 | Mar 31, 2026 |
All 377 Marimed Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.